Table 1 In vitro experimental data of radiosensitization effects
From: CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
| Authors | CDK4/6 inhibitor | Human cell line | Efficacy with radiotherapy |
|---|---|---|---|
| Whiteway et al. [41] | Palbociclib |
Medulloblastoma (Daoy) (ONS-76) |
SF2 a ↓ SER10 b 1.6, SER50 c 1.5 SER10 2.3, SER50 2.3 |
| Hashizume et al. [42] | Palbociclib |
Intracranial ATRT d (BT12) (BT16) |
DEF e 1.16–1.60 DEF 1.18–1.70 |
| Whittaker et al. [43] | Palbociclib |
Glioblastoma (GBM-L1, HW1, RN1, BAH1) | Colony numbers drop to zero |
| Naz et al. [44] | Abemaciclib |
NSCLC (A549, H460, H820, H1975) | DMF f 1.30–1.71 |
| Tao et al. [30] | Palbociclib and Trametinib |
NSCLC (A549, H460) |
Cell survival fraction ↓ Apoptosis ↑ |
| Huang et al. [45] | Palbociclib |
HCC (Hep3B, Huh7) CCA g (HuCCT1) |
Tumor sphere numbers ↓ Colony numbers ↓ |
| Xie et al. [46] | Palbociclib |
NPC (CNE-1) (CNE-2) |
SF2 ↓ SER 1.118–1.475 SER 1.10–1.20 |
| Gottgens et al. [47] | Palbociclib |
HNSCC (UT-SCC-24A) | SER 1.36–1.60 |
| Tai et al. [48] | Ribociclib |
HNSCC (OML1, OML1-R) |
Colony numbers ↓ Cell viability ↓ |
| Fernández-Aroca et al. [49] | Palbociclib |
Breast cancer (MCF-7) Lung cancer (A549) Colorectal cancer (HCT116) | Cell survival fraction ↓ |
| Li et al. [50] | Ribociclib and CA3 |
EAC h (Flo-1 XTR) | Colony numbers ↓ |